<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes and evaluation of hyperkalemia in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes and evaluation of hyperkalemia in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Causes and evaluation of hyperkalemia in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David B Mount, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hyperkalemia is a common clinical problem. Potassium enters the body via oral intake or intravenous infusion, is largely stored in the cells, and is then excreted in the urine. The major causes of hyperkalemia are increased potassium release from the cells and, most often, reduced urinary potassium excretion (<a class="graphic graphic_table graphicRef58157" href="/z/d/graphic/58157.html" rel="external">table 1</a>).</p><p>This topic will review the causes and evaluation of hyperkalemia. The clinical manifestations, treatment, and prevention of hyperkalemia, as well as a detailed discussion of hypoaldosteronism (an important cause of hyperkalemia), are presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2342.html" rel="external">"Clinical manifestations of hyperkalemia in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2332.html" rel="external">"Treatment and prevention of hyperkalemia in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2306.html" rel="external">"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)"</a>.)</p><p></p><p class="headingAnchor" id="H7397120"><span class="h1">BRIEF REVIEW OF POTASSIUM PHYSIOLOGY</span><span class="headingEndMark"> — </span>An understanding of potassium physiology is helpful when approaching patients with hyperkalemia. Total body potassium stores are approximately 3000 mEq or more (50 to 75 mEq/kg body weight) [<a href="#rid1">1</a>]. In contrast to sodium, which is the major cation in the extracellular fluid and has a much lower concentration in the cells, potassium is primarily an intracellular cation, with the cells containing approximately 98 percent of body potassium. The intracellular potassium concentration is approximately 140 mEq/L compared with 4 to 5 mEq/L in the extracellular fluid. The difference in distribution of the two cations is maintained by the Na-K-ATPase pump in the cell membrane, which pumps sodium out of and potassium into the cell in a 3:2 ratio.</p><p>The ratio of the potassium concentrations in the cells and the extracellular fluid is the major determinant of the resting membrane potential across the cell membrane, which sets the stage for the generation of the action potential that is essential for normal neural and muscle function. Thus, both hyperkalemia and hypokalemia can cause muscle paralysis and potentially fatal cardiac arrhythmias. (See  <a class="medical medical_review" href="/z/d/html/2342.html" rel="external">"Clinical manifestations of hyperkalemia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2297.html" rel="external">"Clinical manifestations and treatment of hypokalemia in adults", section on 'Manifestations of hypokalemia'</a>.)</p><p>The causes of hyperkalemia can be best understood after a brief review of normal potassium homeostasis. The plasma potassium concentration is determined by the relationship among potassium intake, the distribution of potassium between the cells and the extracellular fluid, and urinary potassium excretion.</p><p class="headingAnchor" id="H133155018"><span class="h2">Regulation of urinary potassium excretion</span><span class="headingEndMark"> — </span>In normal individuals, dietary potassium is absorbed in the intestines and then largely excreted in the urine, a process that is primarily determined by potassium secretion by the principal cells in the two segments that follow the distal tubule: the connecting segment and cortical collecting tubule (<a class="graphic graphic_figure graphicRef60693" href="/z/d/graphic/60693.html" rel="external">figure 1</a>) [<a href="#rid2">2-5</a>]. There are three major factors that stimulate principal cell potassium secretion [<a href="#rid2">2-5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>An increase in plasma potassium concentration and/or potassium intake</p><p class="bulletIndent1"><span class="glyph">●</span>An increase in aldosterone secretion</p><p class="bulletIndent1"><span class="glyph">●</span>Enhanced delivery of sodium and water to the distal potassium secretory sites</p><p></p><p>Ingestion of a potassium load leads initially to the uptake of most of the excess potassium by cells in muscle and the liver, a process that is facilitated by insulin and the beta-2-adrenergic receptors, both of which increase the activity of Na-K-ATPase pumps in the cell membrane [<a href="#rid4">4-7</a>]. Some of the ingested potassium remains in the extracellular fluid, producing a mild elevation in the plasma potassium concentration.</p><p>The increase in plasma potassium stimulates the secretion of aldosterone, which directly enhances sodium reabsorption and indirectly enhances potassium secretion in the principal cells (<a class="graphic graphic_figure graphicRef60693" href="/z/d/graphic/60693.html" rel="external">figure 1</a>). The increase in sodium reabsorption is mediated primarily by an increase in the number of open sodium channels in the luminal membrane of the principal cells. The reabsorption of cationic sodium makes the lumen more electronegative, thereby enhancing the electrical gradient that promotes the secretion of potassium from the cells into the tubular fluid via potassium channels in the luminal membrane (<a class="graphic graphic_figure graphicRef60693" href="/z/d/graphic/60693.html" rel="external">figure 1</a>). Additionally, the aldosterone-independent activation of apical secretory potassium channels by dietary potassium loading increases the capacity for potassium secretion [<a href="#rid5">5,8</a>]. Aldosterone also increases the number and activity of basolateral Na-K-ATPase pumps in principal cells, which facilitates both sodium reabsorption and potassium secretion. The net effect is that most of the potassium load is excreted within six to eight hours.</p><p>Both cellular uptake and urinary excretion of an acute potassium load are impaired in patients with advanced acute or chronic kidney disease. (See <a class="local">'Acute and chronic kidney disease'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h2">Potassium adaptation</span><span class="headingEndMark"> — </span>Hyperkalemia is a rare occurrence in normal individuals because the cellular and urinary responses prevent significant potassium accumulation in the extracellular fluid. Furthermore, the efficiency of potassium excretion is enhanced if potassium intake is increased, thereby allowing what might otherwise be a fatal potassium load to be tolerated. This phenomenon, called <strong>potassium adaptation</strong>, is mostly due to the ability to more rapidly excrete potassium in the urine [<a href="#rid4">4,5</a>].</p><p>Studies in rats have shown that potassium adaptation begins after a single potassium-containing meal. In one study, for example, rats fed a meal with potassium, when compared with rats given a potassium-free meal, were better able to excrete a potassium load several hours later, leading to a lesser rise in the plasma potassium concentration after the second potassium load [<a href="#rid9">9</a>]. The net effect is that adapted animals excrete more potassium at a given plasma potassium concentration than animals that have not adapted (<a class="graphic graphic_figure graphicRef67129" href="/z/d/graphic/67129.html" rel="external">figure 2</a>).</p><p>The efficacy of potassium adaptation in humans was demonstrated in a study evaluating the response of healthy adults to increasing potassium intake from 100 to 400 mEq/day [<a href="#rid10">10</a>]. Urinary potassium excretion rose to equal intake by the end of the second day, an effect that was accompanied by an elevation in both aldosterone secretion and the plasma potassium concentration (from 3.8 to 4.8 mEq/L) (<a class="graphic graphic_figure graphicRef50808" href="/z/d/graphic/50808.html" rel="external">figure 3</a>). At day 20, urinary potassium excretion continued to match the high level of intake, but plasma aldosterone levels had returned to near baseline, and the plasma potassium concentration had fallen to 4.2 mEq/L (<a class="graphic graphic_figure graphicRef50808" href="/z/d/graphic/50808.html" rel="external">figure 3</a>).</p><p>The increased efficiency of potassium excretion with potassium adaptation appears to be mediated by three changes that occur in the potassium-secreting principal cells in the connecting segment and cortical collecting tubule (<a class="graphic graphic_figure graphicRef60693" href="/z/d/graphic/60693.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>A largely aldosterone-independent increase in the density and activity of apical secretory potassium channels [<a href="#rid3">3,8,11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased Na-K-ATPase activity, which enhances potassium uptake into the cell across the basolateral (peritubular) membrane, thereby increasing the size of the potassium secretory pool [<a href="#rid12">12,13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased activity of apical epithelial sodium channels (ENaC), through both aldosterone-independent and aldosterone-dependent mechanisms [<a href="#rid8">8,11,14</a>]. This induction increases the electrogenic driving force for apical potassium excretion.</p><p></p><p>Additionally, by inhibiting the function of the thiazide-sensitive Na-Cl cotransporter (NCC) within the distal convoluted tubule, potassium loading and hyperkalemia increase the delivery of sodium to principal cells within the downstream connecting tubule, thereby increasing potassium secretion. NCC is tightly regulated by complex interactions among potassium, the renin-angiotensin-aldosterone system, and the chloride-sensitive WNK signaling system [<a href="#rid5">5,15-17</a>].</p><p class="headingAnchor" id="H367758506"><span class="h2">Conclusions</span><span class="headingEndMark"> — </span>The preceding observations lead to the following conclusions concerning the causes of hyperkalemia:</p><p class="bulletIndent1"><span class="glyph">●</span>Increasing potassium intake alone is <strong>not</strong> a common cause of hyperkalemia unless it occurs acutely. Acute hyperkalemia can rarely be induced (primarily in infants because of their small size) by the administration of potassium penicillin as an intravenous bolus, the accidental ingestion of a potassium-containing salt substitute, or the use of stored blood for exchange transfusions. In addition, moderate increases in potassium intake can be an important contributor to the development of hyperkalemia in patients with impaired potassium excretion due, for example, to hypoaldosteronism and/or kidney function impairment. (See <a class="local">'Reduced urinary potassium excretion'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The net release of potassium from the cells (due to enhanced release or decreased entry) can, if large enough (eg, increased tissue breakdown), cause a transient elevation in the serum potassium concentration. (See <a class="local">'Increased potassium release from cells'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistent hyperkalemia requires <strong>impaired urinary potassium excretion</strong>. In view of the factors described above, this is generally associated with a reduction in aldosterone secretion or responsiveness, acute or chronic kidney disease, and/or diminished delivery of sodium and water to the distal potassium secretory sites. (See <a class="local">'Reduced urinary potassium excretion'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potassium secretion is tightly regulated by a complex interplay among individual mediators in the renin-angiotensin-aldosterone system, sodium and potassium transport pathways, and the chloride-sensitive WNK signaling system [<a href="#rid5">5,15-17</a>]. Due to aldosterone-independent regulatory pathways in potassium homeostasis, hyperkalemia is not a universal feature of hypoaldosteronism.</p><p></p><p>Many of the causes of hyperkalemia are discussed in detail elsewhere and will only be listed below (<a class="graphic graphic_table graphicRef58157" href="/z/d/graphic/58157.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H3"><span class="h1">INCREASED POTASSIUM RELEASE FROM CELLS</span></p><p class="headingAnchor" id="H4"><span class="h2">Pseudohyperkalemia</span><span class="headingEndMark"> — </span>Pseudohyperkalemia refers to those conditions in which the elevation in the measured serum potassium concentration is usually due to potassium movement out of the cells during or after the blood specimen has been drawn [<a href="#rid18">18</a>]. The possible presence of pseudohyperkalemia should be suspected when there is no apparent cause for the hyperkalemia in an asymptomatic patient who has no electrocardiographic manifestations of hyperkalemia.</p><p class="headingAnchor" id="H156422759"><span class="h3">Technique of blood drawing</span><span class="headingEndMark"> — </span>Pseudohyperkalemia can be seen in a variety of settings. The most common causes are related to the technique of blood drawing and can involve one or both of the following mechanisms:</p><p class="bulletIndent1"><span class="glyph">●</span>Mechanical trauma during venipuncture can result in the release of potassium from red cells and a characteristic reddish tint of the serum due to the concomitant release of hemoglobin.</p><p></p><p class="bulletIndent1">Red serum can also represent severe intravascular hemolysis rather than a hemolyzed specimen [<a href="#rid19">19</a>]. When intravascular hemolysis is present, the measured serum potassium may represent the true circulating value.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potassium moves out of muscle cells with exercise. As a result, repeated fist clenching during blood drawing can acutely raise the serum potassium concentration by more than 1 to 2 mEq/L in that forearm [<a href="#rid20">20</a>]. (See <a class="local">'Exercise'</a> below.)</p><p></p><p>In these settings, venipuncture without a tourniquet, repeated fist clenching, or trauma will demonstrate the true serum potassium concentration [<a href="#rid21">21</a>]. If a tourniquet is required, the tourniquet should be released after the needle has entered the vein, followed by waiting for <strong>one to two minutes</strong> before drawing the blood sample.</p><p>Less common causes of an increase in serum potassium related to collection and storage include cooling of the sample and specimen deterioration because of prolonged length of storage [<a href="#rid18">18,22</a>].</p><p class="headingAnchor" id="H156422766"><span class="h3">Other causes</span><span class="headingEndMark"> — </span>There are several other settings in which pseudohyperkalemia can occur:</p><p class="bulletIndent1"><span class="glyph">●</span>Potassium moves out of platelets after clotting has occurred. Thus, the serum potassium concentration normally exceeds the true value in plasma by 0.1 to 0.5 mEq/L [<a href="#rid23">23</a>]. Although this difference in normal individuals is not clinically important, the increase in the measured serum potassium concentration can be much greater in normokalemic patients with thrombocytosis, rising by approximately 0.15 mEq/L per 100,000/microL elevation in the platelet count [<a href="#rid23">23</a>]. In one study, hyperkalemia in a serum sample occurred in 34 percent of patients with a platelet count above 500,000/microL compared with 9 percent of patients with a platelet count less than 250,000/microL [<a href="#rid23">23</a>]. The concentration of potassium in plasma (obtained by centrifugation of heparinized, unclotted blood) was normal.</p><p></p><p class="bulletIndent1">A similar phenomenon has been reported in acute myeloid leukemia [<a href="#rid24">24</a>]. However, <strong>hypokalemia</strong> is more common in this disorder, due to movement of potassium into rapidly proliferating cells after the blood has been drawn (pseudohypokalemia) or to renal potassium wasting (true hypokalemia). (See  <a class="medical medical_review" href="/z/d/html/4510.html" rel="external">"Acute myeloid leukemia: Overview of complications", section on 'Hypokalemia'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High white blood cell counts (&gt;120,000/microL) caused by chronic lymphocytic leukemia can lead to falsely elevated potassium concentrations due to cell fragility. Unlike thrombocytosis, this form of pseudohyperkalemia occurs in<strong> both</strong> serum and plasma samples and may be more prominent when blood is sampled in heparinized tubes [<a href="#rid25">25</a>]. Centrifugation of a heparinized tube causes in vitro cell destruction and release of potassium as these cells are freely suspended in plasma.</p><p></p><p class="bulletIndent1">Accurate assessment of the potassium concentration in this setting can be achieved by allowing clotting to separate serum (plasma without the clotting factors) from cells <strong>before</strong> centrifugation. The fibrin clot entraps and protects fragile leukemic cells, minimizing cell lysis.</p><p></p><p class="bulletIndent1">Pseudohyperkalemia in patients with very high white blood cell counts due to leukemia or lymphoma has also been reported after mechanical disruption of white blood cells during transport of blood samples via pneumatic tube systems [<a href="#rid26">26,27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potassium can move out of red cells after the specimen is collected in patients with hereditary (familial) forms of pseudohyperkalemia, which are caused by an increase in the passive potassium permeability of erythrocytes. Pseudohyperkalemia may be the only manifestation of the disorder, or it may be accompanied by abnormal red cell morphology (eg, stomatocytosis), varying degrees of hemolysis, and/or perinatal edema in specific kindreds. This genetically heterogeneous condition is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7068.html" rel="external">"Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)", section on 'Clinical manifestations'</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Metabolic acidosis</span><span class="headingEndMark"> — </span>In patients with metabolic acidosis other than organic acidosis due to lactic acidosis or ketoacidosis, buffering of excess hydrogen ions in the cells leads to potassium movement into the extracellular fluid, a transcellular shift that is obligated in part by the need to maintain electroneutrality (<a class="graphic graphic_figure graphicRef68866" href="/z/d/graphic/68866.html" rel="external">figure 4</a>). (See  <a class="medical medical_review" href="/z/d/html/2353.html" rel="external">"Potassium balance in acid-base disorders", section on 'Metabolic acidosis'</a>.)</p><p>Although this shift will tend to raise the plasma potassium concentration, some patients have concurrent potassium losses due to gastrointestinal disease (eg, diarrhea) or increased urinary losses (eg, renal tubular acidosis [RTA]). In these settings, the measured serum potassium concentration may be normal or reduced despite the presence of metabolic acidosis. However, the plasma potassium will be higher than it would have been if the same degree of potassium loss had occurred in the absence of metabolic acidosis. (See  <a class="medical medical_review" href="/z/d/html/2327.html" rel="external">"Overview and pathophysiology of renal tubular acidosis and the effect on potassium balance"</a>.)</p><p class="headingAnchor" id="H446278642"><span class="h3">Absent effect in lactic acidosis or ketoacidosis</span><span class="headingEndMark"> — </span>In contrast to the above finding, hyperkalemia due to an acidosis-induced shift of potassium from the cells into the extracellular fluid does <strong>not</strong> occur in the organic acidoses lactic acidosis and ketoacidosis [<a href="#rid28">28-31</a>]. A possible contributory factor in both disorders is the ability of the organic anion and the hydrogen ion to enter into the cell via a sodium-organic anion cotransporter. The transport mechanisms involved and how they minimize potassium movement out of the cells are discussed in detail elsewhere [<a href="#rid29">29</a>].</p><p>As described below, the development of hyperkalemia in patients with diabetic ketoacidosis is primarily due to insulin deficiency and hyperosmolality, not acidemia. (See <a class="local">'Insulin deficiency, hyperglycemia, and hyperosmolality'</a> below and  <a class="medical medical_review" href="/z/d/html/1792.html" rel="external">"Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis", section on 'Serum potassium'</a>.)</p><p class="headingAnchor" id="H129571552"><span class="h3">Smaller effect in respiratory acidosis</span><span class="headingEndMark"> — </span>Hyperkalemia due to respiratory acidosis is not a common clinical problem. The effect of respiratory acidosis on the plasma potassium concentration has been primarily evaluated in acute rather than chronic respiratory acidosis. In a review of the available human data, respiratory acidosis produced <strong>no</strong> significant effect on the plasma potassium, although the degree of acidemia in the reviewed studies was usually mild (fall in plasma pH approximately 0.1); in addition, the increase in plasma potassium for a given reduction in pH was smaller when the fall in pH was induced by respiratory as compared with metabolic acidosis [<a href="#rid28">28</a>]. The effect of respiratory acidosis on the plasma potassium is greater with more severe acidosis and with a longer duration of acidosis [<a href="#rid32">32</a>]. The mechanisms responsible for the lesser increase in plasma potassium in respiratory acidosis compared with metabolic acidosis are not well defined [<a href="#rid29">29</a>].</p><p>Studies in animal models of acute respiratory acidosis have shown variable increases in plasma potassium with the severity and duration of the acidosis. The following illustrates the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study in dogs, severe acute respiratory acidosis (a decrease in mean plasma pH from 7.4 to 7) had no effect on the plasma potassium at 10 minutes but, at two and six hours, the plasma potassium had increased from 4 to 6 mEq/L (approximately 0.5 mEq/L per 0.1 reduction in plasma pH) [<a href="#rid33">33</a>]. The increase in plasma potassium was due to potassium movement out of cells and was approximately twice as large when the ureters were ligated, suggesting a role for urinary excretion of some of the excess potassium.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As might be expected, other studies in dogs with less severe acute respiratory acidosis found no [<a href="#rid34">34</a>] or only small elevations in the plasma potassium concentration [<a href="#rid35">35</a>].</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Insulin deficiency, hyperglycemia, and hyperosmolality</span><span class="headingEndMark"> — </span>Insulin promotes potassium entry <strong>into</strong> cells. Thus, the ingestion of glucose (which stimulates endogenous insulin secretion) minimizes the rise in the serum potassium concentration induced by concurrent potassium intake (<a class="graphic graphic_figure graphicRef52424" href="/z/d/graphic/52424.html" rel="external">figure 5</a>) [<a href="#rid36">36</a>], while glucose ingestion alone in patients without diabetes modestly lowers the serum potassium (<a class="graphic graphic_figure graphicRef64207" href="/z/d/graphic/64207.html" rel="external">figure 6</a>) [<a href="#rid37">37</a>].</p><p>The findings are different in uncontrolled diabetes mellitus. In this setting, the combination of insulin deficiency (either impaired secretion or insulin resistance) and hyperosmolality induced by hyperglycemia frequently leads to hyperkalemia even though there may be marked potassium depletion due to urinary losses caused by the osmotic diuresis (<a class="graphic graphic_figure graphicRef64207" href="/z/d/graphic/64207.html" rel="external">figure 6</a>) [<a href="#rid37">37-39</a>]. (See  <a class="medical medical_review" href="/z/d/html/1792.html" rel="external">"Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis", section on 'Serum potassium'</a>.)</p><p>The increase in plasma osmolality results in osmotic water movement from the cells into the extracellular fluid. This is accompanied by potassium movement out of the cells by two proposed mechanisms:</p><p class="bulletIndent1"><span class="glyph">●</span>The loss of cell water raises the cell potassium concentration, thereby creating a favorable gradient for passive potassium exit through potassium channels in the cell membrane.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The friction forces between solvent (water) and solute can result in potassium being carried along with water through the water pores in the cell membrane. This phenomenon of solvent drag is independent of the electrochemical gradient for potassium diffusion.</p><p></p><p class="headingAnchor" id="H90534304"><span class="h3">Causes other than diabetes mellitus</span><span class="headingEndMark"> — </span>Disorders other than diabetes mellitus have been associated with hyperkalemia due to insulin deficiency and/or hyperosmolality. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Insulin levels fall in response to therapy with somatostatin or the somatostatin agonist, <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a>, and can lead to elevations in serum potassium [<a href="#rid40">40-43</a>]. The magnitude of this effect varies with the clinical setting. In one study, for example, the mean increase in serum potassium was 0.5 to 0.6 mEq/L in normal individuals and patients with type 2 diabetes; in contrast, there was no change in serum potassium in patients with type 1 diabetes since they make little or no insulin [<a href="#rid40">40</a>]. The effect of somatostatin or octreotide is much greater in patients with end-stage kidney disease (ESKD) requiring dialysis in whom the serum potassium can rise above 7 mEq/L [<a href="#rid41">41,42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fasting is associated with an appropriate reduction in insulin levels that can lead to an increase in plasma potassium. This may be a particular problem in patients on dialysis. (See <a class="local">'Acute and chronic kidney disease'</a> below.)</p><p></p><p class="bulletIndent1">The risk of hyperkalemia during preoperative fasting can be minimized by the administration of insulin and glucose in patients with diabetes, or glucose alone in patients without diabetes (<a class="graphic graphic_figure graphicRef64207" href="/z/d/graphic/64207.html" rel="external">figure 6</a>) [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition to hyperglycemia induced by insulin deficiency, hyperkalemia induced by hyperosmolality has also been described with hypernatremia [<a href="#rid44">44</a>], sucrose contained in intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> [<a href="#rid45">45</a>], radiocontrast media [<a href="#rid46">46</a>], and the administration of hypertonic <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">mannitol</a> [<a href="#rid47">47</a>]. Most of the reported patients had kidney failure. (See  <a class="medical medical_review" href="/z/d/html/2333.html" rel="external">"Complications of mannitol therapy", section on 'Volume expansion, hyponatremia, hyperkalemia, hypokalemia, and metabolic acidosis'</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Increased tissue catabolism</span><span class="headingEndMark"> — </span>Any cause of increased tissue breakdown leads to the release of intracellular potassium into the extracellular fluid. Hyperkalemia can occur in this setting, particularly if kidney failure is also present. Clinical examples include trauma (including noncrush trauma), rhabdomyolysis, the administration of cytotoxic or radiation therapy to patients with lymphoma or leukemia (the tumor lysis syndrome), and severe accidental hypothermia [<a href="#rid48">48-50</a>]. (See  <a class="medical medical_review" href="/z/d/html/7227.html" rel="external">"Crush-related acute kidney injury", section on 'Biochemical abnormalities'</a> and  <a class="medical medical_review" href="/z/d/html/1154.html" rel="external">"Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/178.html" rel="external">"Accidental hypothermia in adults", section on 'Pathophysiology'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Beta blockers</span><span class="headingEndMark"> — </span>Increased beta-2-adrenergic activity drives potassium into the cells and lowers the serum potassium. (See  <a class="medical medical_review" href="/z/d/html/2341.html" rel="external">"Causes of hypokalemia in adults", section on 'Elevated beta-adrenergic activity'</a>.)</p><p>Beta blockers interfere with the beta-2-adrenergic facilitation of potassium uptake by the cells, particularly after a potassium load (<a class="graphic graphic_figure graphicRef62538" href="/z/d/graphic/62538.html" rel="external">figure 7</a>) [<a href="#rid51">51,52</a>]. An increase in serum potassium is primarily seen with nonselective beta blockers (such as <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> and <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">labetalol</a>). In contrast, beta-1-selective blockers such as <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> have little effect on serum potassium since beta-2 receptor activity remains intact [<a href="#rid53">53</a>].</p><p>The rise in serum potassium with nonselective beta blocker therapy is usually less than 0.5 mEq/L. True hyperkalemia is rare unless there is a large potassium load, marked exercise (as described in the next section), or an additional defect in potassium handling that prevents excretion of the excess extracellular potassium, such as hypoaldosteronism or kidney failure [<a href="#rid52">52,54</a>]. In one report, for example, three kidney transplant recipients developed severe hyperkalemia after the administration of <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">labetalol</a> for postoperative hypertension [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Exercise</span><span class="headingEndMark"> — </span>Potassium is normally released from muscle cells during exercise. The increase in plasma potassium is rarely important clinically, with the one major exception that fist clenching during blood drawing can interfere with accurate assessment of the serum potassium concentration. Repeated fist clenching during blood drawing can acutely raise the serum potassium concentration by more than 1 mEq/L in that forearm, thereby representing a form of pseudohyperkalemia [<a href="#rid20">20</a>]. (See <a class="local">'Pseudohyperkalemia'</a> above.)</p><p>The increase in plasma potassium during exercise may be mediated by two factors:</p><p class="bulletIndent1"><span class="glyph">●</span>A delay between potassium exit from the cells during depolarization and subsequent reuptake into the cells via the Na-K-ATPase pump.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>With marked exercise, an increased number of open potassium channels in the cell membrane. These channels are inhibited by ATP, an effect that is removed by the exercise-induced decline in ATP levels [<a href="#rid55">55</a>].</p><p></p><p>The release of potassium during exercise may have a physiologically important role. The <strong>local</strong> increase in potassium concentration has a vasodilator effect, thereby increasing blood flow and energy delivery to the exercising muscle.</p><p>The degree of elevation in the plasma potassium concentration in the <strong>systemic circulation</strong> is less pronounced and varies directly with the degree of exercise: 0.3 to 0.4 mEq/L with slow walking; 0.7 to 1.2 mEq/L with moderate exertion (including prolonged aerobic exercise with marathon running); and as much as 2 mEq/L following exercise to exhaustion [<a href="#rid54">54,56-59</a>], which may be associated with both ECG changes [<a href="#rid58">58</a>] and lactic acidosis [<a href="#rid59">59</a>].</p><p>The peak increase in plasma potassium during exercise is <strong>less</strong> pronounced with prior physical conditioning (perhaps due to increased Na-K-ATPase activity) [<a href="#rid60">60</a>] and <strong>more</strong> pronounced in patients treated with nonselective beta blockers [<a href="#rid56">56</a>] or those with ESKD even though there is often a lesser degree of attained exercise [<a href="#rid61">61</a>]. (See <a class="local">'Beta blockers'</a> above.)</p><p>The rise in plasma potassium concentration induced by exercise is reversed after several minutes of rest and is typically associated with a mild rebound hypokalemia (averaging 0.4 to 0.5 mEq/L below the baseline level) [<a href="#rid57">57-59</a>]. It has been suggested that the changes in plasma potassium might be arrhythmogenic in susceptible patients, such as those with angina pectoris [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Hyperkalemic periodic paralysis</span><span class="headingEndMark"> — </span>Hyperkalemic periodic paralysis is an autosomal dominant disorder in which episodes of weakness or paralysis are usually precipitated by cold exposure, rest after exercise, fasting, or the ingestion of small amounts of potassium. The most common abnormality in hyperkalemic periodic paralysis is a point mutation in the gene for the alpha subunit of the skeletal muscle cell sodium channel. (See  <a class="medical medical_review" href="/z/d/html/5152.html" rel="external">"Hyperkalemic periodic paralysis", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Other</span><span class="headingEndMark"> — </span>Other rare causes of hyperkalemia due to translocation of potassium from the cells into the extracellular fluid include:</p><p class="bulletIndent1"><span class="glyph">●</span>Digitalis overdose, due to dose-dependent inhibition of the Na-K-ATPase pump [<a href="#rid62">62</a>]. Hyperkalemia can also occur after poisoning with structurally related digitalis glycosides, as may occur after ingestion of the plants, common oleander or yellow oleander [<a href="#rid63">63</a>], or extracts of the cane toad, Bufo marinus (bufadienolides) [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/z/d/html/319.html" rel="external">"Digitalis (cardiac glycoside) poisoning", section on 'Electrolyte abnormalities'</a> and  <a class="medical medical_review" href="/z/d/html/6507.html" rel="external">"Potentially toxic plant ingestions in children: Clinical manifestations and evaluation", section on 'Cardiac glycosides (eg, oleander, foxglove)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Red cell transfusion, due to leakage of potassium out of the red cells during storage. Hyperkalemia primarily occurs in infants and with massive transfusions. (See  <a class="medical medical_review" href="/z/d/html/5938.html" rel="external">"Red blood cell transfusion in infants and children: Administration and complications", section on 'Metabolic toxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration of <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a> to patients with burns, extensive trauma, prolonged immobilization, chronic infection, or neuromuscular disease [<a href="#rid65">65-67</a>]. Acetylcholine receptors are normally concentrated within the neuromuscular junction, and the efflux of intracellular potassium caused by depolarization of these receptors is confined to this space. Hyperkalemia occurs when succinylcholine is given under conditions that cause upregulation and widespread distribution of acetylcholine receptors throughout the entire muscle membrane [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration of arginine hydrochloride, which is metabolized in part to hydrochloric acid and has been used to treat refractory metabolic alkalosis. The entry of cationic arginine into the cells presumably obligates potassium exit to maintain electroneutrality [<a href="#rid68">68</a>]. The drug <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">aminocaproic acid</a> can cause hyperkalemia by the same mechanism since it is structurally similar to arginine [<a href="#rid69">69,70</a>]. (See  <a class="medical medical_review" href="/z/d/html/2345.html" rel="external">"Treatment of metabolic alkalosis", section on 'Hydrochloric acid in selected patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of drugs that activate ATP-dependent potassium channels in cell membranes, such as calcineurin inhibitors (eg, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>), nicorandil, and <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">isoflurane</a> [<a href="#rid71">71</a>]. In particular, there are multiple reports of hyperkalemia from nicorandil in susceptible patients [<a href="#rid72">72-74</a>]. As described elsewhere, other mechanisms are also involved in calcineurin inhibitor-induced hyperkalemia, including hyporeninemic hypoaldosteronism and inhibition of the luminal potassium channel through which potassium is secreted (<a class="graphic graphic_figure graphicRef60693" href="/z/d/graphic/60693.html" rel="external">figure 1</a>). (See <a class="local">'Reduced aldosterone secretion'</a> below and  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity", section on 'Hyperkalemia'</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h1">REDUCED URINARY POTASSIUM EXCRETION</span><span class="headingEndMark"> — </span>Urinary potassium excretion is primarily mediated by potassium secretion in the principal cells in the two segments that follow the distal tubule: the connecting segment and cortical collecting tubule (<a class="graphic graphic_figure graphicRef60693" href="/z/d/graphic/60693.html" rel="external">figure 1</a>). Three major factors are required for adequate potassium secretion at these sites: <strong>adequate</strong> <strong>aldosterone secretion</strong>, <strong>adequate responsiveness to aldosterone</strong>, and <strong>adequate distal sodium and water delivery </strong>[<a href="#rid75">75</a>]. The widely used term hypoaldosteronism applies to both reduced aldosterone secretion and reduced response to aldosterone. (See <a class="local">'Brief review of potassium physiology'</a> above.)</p><p>The four major causes of hyperkalemia due to reduced urinary potassium secretion are:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced aldosterone secretion</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced response to aldosterone (aldosterone resistance)</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced distal sodium and water delivery as occurs in effective arterial blood volume depletion</p><p class="bulletIndent1"><span class="glyph">●</span>Acute and chronic kidney disease in which one or more of the above factors are present</p><p></p><p>Other mechanisms for reduced urinary potassium secretion have rarely been described. (See <a class="local">'Other mechanisms of impaired potassium secretion'</a> below.)</p><p>In addition to directly causing hyperkalemia, impaired urinary potassium excretion can also contribute to hyperkalemia induced by potassium release from the cells (<a class="graphic graphic_table graphicRef58157" href="/z/d/graphic/58157.html" rel="external">table 1</a>). (See <a class="local">'Increased potassium release from cells'</a> above.)</p><p class="headingAnchor" id="H13"><span class="h2">Reduced aldosterone secretion</span><span class="headingEndMark"> — </span>Any cause of decreased aldosterone release, such as that induced by hyporeninemic hypoaldosteronism or certain drugs, can diminish the efficiency of potassium secretion and lead to hyperkalemia and metabolic acidosis (called type 4 renal tubular acidosis [RTA]) (<a class="graphic graphic_table graphicRef82440" href="/z/d/graphic/82440.html" rel="external">table 2</a>). Drugs commonly implicated include angiotensin inhibitors [<a href="#rid76">76</a>], nonsteroidal antiinflammatory drugs, calcineurin inhibitors, and heparin. (See  <a class="medical medical_review" href="/z/d/html/2306.html" rel="external">"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)", section on 'Etiology'</a>.)</p><p>Hyperkalemia is a common problem in patients treated with the calcineurin inhibitors, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>. These drugs can induce hyporeninemic hypoaldosteronism and can also interfere with the effect of aldosterone on the potassium-secreting cells in the connecting segment and cortical collecting tubule. (See  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity", section on 'Hyperkalemia'</a>.)</p><p>The rise in plasma potassium concentration induced by reductions in aldosterone secretion or aldosterone response directly stimulates potassium secretion, partially overcoming the relative absence of aldosterone. The net effect is that the rise in the plasma potassium concentration is generally small in patients with normal kidney function but can be clinically important in the presence of underlying kidney function impairment and/or other causes of hyperkalemia (<a class="graphic graphic_table graphicRef58157" href="/z/d/graphic/58157.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H774689278"><span class="h2">Reduced response to aldosterone</span><span class="headingEndMark"> — </span>There are a number of causes of hyperkalemia that are due to a reduced response to aldosterone, also called aldosterone or mineralocorticoid resistance. The most common are the administration of potassium-sparing diuretics and acute and chronic kidney disease in which other factors may also contribute. (See <a class="local">'Acute and chronic kidney disease'</a> below.)</p><p class="headingAnchor" id="H774689287"><span class="h3">Potassium-sparing diuretics</span><span class="headingEndMark"> — </span>Two classes of diuretic medications impair renal potassium secretion despite normal or high levels of aldosterone: aldosterone antagonists that compete with aldosterone for receptor sites (<a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> and <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">eplerenone</a>), and drugs that directly block the sodium channels in the apical (luminal) membrane of the principal cells in the collecting tubule (<a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a> and <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">triamterene</a>) (<a class="graphic graphic_figure graphicRef60693" href="/z/d/graphic/60693.html" rel="external">figure 1</a>).</p><p>The antibiotics <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> (TMP) and <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">pentamidine</a> share structural similarity with <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a> and also inhibit apical sodium channels [<a href="#rid77">77,78</a>]; in perfused cortical collecting ducts, TMP inhibits both sodium reabsorption and potassium secretion [<a href="#rid79">79</a>]. Hyperkalemia associated with TMP was initially reported in patients with HIV treated for <em>Pneumocystis</em> pneumonia with high doses of <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> [<a href="#rid80">80</a>]. Standard doses of TMP may also produce hyperkalemia; in one study of hospitalized patients, for example, hyperkalemia occurred in greater than 50 percent, with serum potassium concentrations &gt;5.5 mmol/L in 21 percent [<a href="#rid81">81</a>]. (See  <a class="medical medical_review" href="/z/d/html/493.html" rel="external">"Trimethoprim-sulfamethoxazole: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/2306.html" rel="external">"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)", section on 'Antibiotics'</a>.) </p><p>Risk factors for hyperkalemia in patients treated with potassium-sparing diuretics include kidney function impairment, hyporeninemic hypoaldosteronism, and treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). </p><p class="headingAnchor" id="H17"><span class="h3">Voltage-dependent renal tubular acidosis</span><span class="headingEndMark"> — </span>In some patients with distal RTA, the primary defect is impaired sodium reabsorption in the principal cells in the two segments that follow the distal tubule (the connecting segment and the cortical collecting tubule). The movement of sodium from the lumen into the principal cells makes the lumen electronegative, thereby promoting the secretion of both hydrogen ions and potassium (<a class="graphic graphic_figure graphicRef60693" href="/z/d/graphic/60693.html" rel="external">figure 1</a>). In contrast, an impairment in sodium reabsorption will reduce both hydrogen and potassium secretion, which will promote the development of metabolic acidosis and hyperkalemia. This disorder, which has been called voltage-dependent RTA, has been associated with urinary tract obstruction [<a href="#rid82">82</a>], lupus nephritis [<a href="#rid83">83</a>], sickle cell disease [<a href="#rid84">84</a>], and renal amyloidosis [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/z/d/html/2327.html" rel="external">"Overview and pathophysiology of renal tubular acidosis and the effect on potassium balance"</a>.)</p><p>A somewhat similar defect is induced by hypoaldosteronism since aldosterone normally increases the number of open sodium channels in the luminal membrane. In contrast to hypoaldosteronism, voltage-dependent RTA is associated with normal or even high aldosterone levels and an inability to normally acidify the urine, as the urine pH is above 5.5. (See <a class="local">'Reduced aldosterone secretion'</a> above and  <a class="medical medical_review" href="/z/d/html/2328.html" rel="external">"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis"</a>.)</p><p class="headingAnchor" id="H270421097"><span class="h3">Pseudohypoaldosteronism type 1</span><span class="headingEndMark"> — </span>Pseudohypoaldosteronism type 1 is a rare hereditary disorder that is characterized by aldosterone resistance. The autosomal recessive form affects the collecting tubule sodium channel (ENaC) (<a class="graphic graphic_figure graphicRef60693" href="/z/d/graphic/60693.html" rel="external">figure 1</a>), and the autosomal dominant form in most patients affects the mineralocorticoid receptor. (See  <a class="medical medical_review" href="/z/d/html/2306.html" rel="external">"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)", section on 'Pseudohypoaldosteronism type 1'</a>.)</p><p class="headingAnchor" id="H270420126"><span class="h2">Reduced distal sodium and water delivery</span><span class="headingEndMark"> — </span>Even in the presence of normal or increased plasma aldosterone levels, potassium secretion and therefore urinary potassium excretion can be impaired if there is a substantial reduction in sodium and water delivery to the potassium secretory sites in the distal nephron (connecting segment and cortical collecting tubule). As an example, potassium secretion by perfused rabbit cortical collecting ducts is dramatically inhibited at a luminal sodium concentration of 8 mmol/L and essentially stops at a luminal sodium concentration of 0 mmol/L [<a href="#rid86">86</a>]. Dietary sodium intake also influences potassium excretion; the potassium secretory capacity is enhanced by excess sodium intake and reduced by sodium restriction [<a href="#rid87">87</a>].</p><p>The most common cause of reduced distal sodium and water delivery is effective arterial blood volume depletion, which may be accompanied by other factors that promote the development of hyperkalemia. Measurement of urinary sodium concentration, combined with a therapeutic response to <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> hydration, can help confirm this pathophysiology.</p><p class="headingAnchor" id="H270420133"><span class="h3">Effective arterial blood volume depletion</span><span class="headingEndMark"> — </span>The effective arterial blood volume (also called effective circulating volume) refers to the arterial blood volume that is effectively perfusing the tissues. Effective arterial blood volume depletion includes any cause of true volume depletion (eg, gastrointestinal or renal losses) as well as heart failure and cirrhosis in which decreased tissue perfusion is due to a reduced cardiac output and vasodilation, respectively. (See  <a class="medical medical_review" href="/z/d/html/2307.html" rel="external">"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)", section on 'Effective arterial blood volume'</a>.)</p><p>Any cause of effective arterial blood volume depletion can lead sequentially to decreased delivery of sodium and water to the sites of potassium secretion in the distal nephron (connecting segment and cortical collecting tubule), impaired potassium secretion into the tubular lumen, and hyperkalemia (<a class="graphic graphic_figure graphicRef60693" href="/z/d/graphic/60693.html" rel="external">figure 1</a>) [<a href="#rid88">88,89</a>]. (See <a class="local">'Brief review of potassium physiology'</a> above.) However, the effect of impaired potassium secretion can be minimized or overcome, possibly resulting in hypokalemia, if there are concurrent potassium losses, as in patients with vomiting or diarrhea, or those treated with diuretic therapy.</p><p>In addition to decreased distal delivery of sodium and water, other potentially important contributing factors to hyperkalemia in patients with heart failure and cirrhosis include angiotensin inhibitor therapy in heart failure (but not cirrhosis) and aldosterone antagonists in both heart failure and cirrhosis. (See  <a class="medical medical_review" href="/z/d/html/2365.html" rel="external">"Renal effects of ACE inhibitors in heart failure", section on 'Hyperkalemia'</a> and  <a class="medical medical_review" href="/z/d/html/1256.html" rel="external">"Ascites in adults with cirrhosis: Initial therapy", section on 'Avoidance of angiotensin inhibition'</a> and  <a class="medical medical_review" href="/z/d/html/1256.html" rel="external">"Ascites in adults with cirrhosis: Initial therapy", section on 'Diuretic regimen'</a> and  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Mineralocorticoid receptor antagonist'</a>.)</p><p class="headingAnchor" id="H270425989"><span class="h2">Acute and chronic kidney disease</span><span class="headingEndMark"> — </span>Hyperkalemia is a common complication of acute and chronic kidney disease. In patients with acute kidney injury, hyperkalemia is most prevalent in oliguric patients who also have increased potassium release from cells due, for example, to rhabdomyolysis or tumor lysis syndrome.</p><p>In patients with chronic kidney disease, the ability to excrete potassium at near-normal levels without the development of hyperkalemia generally persists as long as both the secretion of and responsiveness to aldosterone are intact and distal delivery of sodium and water are maintained [<a href="#rid90">90</a>]. Hyperkalemia is most commonly seen in patients who are oliguric or have an additional problem such as a high-potassium diet, increased tissue breakdown, reduced aldosterone secretion or responsiveness, or fasting in patients on dialysis, which may both lower insulin levels and cause resistance to beta-adrenergic stimulation of potassium uptake [<a href="#rid38">38,90-92</a>]. In patients on dialysis who fasted prior to surgery, the administration of insulin and glucose or, to a lesser degree, glucose alone in patients without diabetes can minimize the elevation in the serum potassium concentration [<a href="#rid92">92</a>]. (See <a class="local">'Insulin deficiency, hyperglycemia, and hyperosmolality'</a> above.)</p><p>Impaired cell uptake of potassium also contributes to the development of hyperkalemia in advanced kidney failure (<a class="graphic graphic_figure graphicRef52424" href="/z/d/graphic/52424.html" rel="external">figure 5</a>). Diminished Na-K-ATPase activity may be particularly important in this setting. How this occurs is not clear, but retained uremic toxins may decrease the transcription of mRNA for the alpha1 isoform of the Na-K-ATPase pump in skeletal muscle [<a href="#rid91">91,93,94</a>].</p><p class="headingAnchor" id="H270420140"><span class="h2">Multiple factors</span><span class="headingEndMark"> — </span>The presence of multiple factors that impair potassium secretion can lead to more severe and possibly life-threatening hyperkalemia. One setting in which this can occur is in patients with moderate to severe heart failure [<a href="#rid95">95-99</a>]. These patients often have reduced distal sodium and water delivery due to the associated kidney hypoperfusion, relatively decreased aldosterone release (from treatment with ACE inhibitors and/or ARBs), and reduced aldosterone effect (from treatment with <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> or <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">eplerenone</a>) [<a href="#rid98">98</a>]. (See  <a class="medical medical_review" href="/z/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers", section on 'Hyperkalemia'</a> and  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a> and  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Mineralocorticoid receptor antagonist'</a>.)</p><p class="headingAnchor" id="H270419983"><span class="h2">Other mechanisms of impaired potassium secretion</span><span class="headingEndMark"> — </span>In addition to the common mechanisms of hyperkalemia due to reduced urinary potassium excretion described above, there are other, less common causes of hyperkalemia in which urinary potassium excretion is impaired due to mechanisms not directly related to reduced secretion of or response to aldosterone or to reduced distal sodium and water delivery.</p><p class="headingAnchor" id="H18"><span class="h3">Selective impairment in potassium secretion</span><span class="headingEndMark"> — </span>Some patients with hyperkalemia have impaired urinary potassium excretion despite normal aldosterone release and normal distal sodium and water delivery. This seemingly selective impairment in potassium secretion, which does not respond to exogenous mineralocorticoid, has been described with lupus nephritis, acute transplant rejection, and sickle cell disease [<a href="#rid100">100-102</a>]. These patients do not have sodium wasting and have a normal antinatriuretic response to mineralocorticoids, indicating a selective potassium defect, <strong>not</strong> aldosterone resistance [<a href="#rid101">101,102</a>]. In at least some cases, the potassium secretory defect may be due to interstitial nephritis [<a href="#rid100">100</a>].</p><p>A selective impairment in potassium secretion can also occur in patients treated with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>. One or more mechanisms involved in tubular potassium secretion may be impaired. (See  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity", section on 'Hyperkalemia'</a>.)</p><p class="headingAnchor" id="H774690471"><span class="h3">Pseudohypoaldosteronism type 2 (Gordon's syndrome)</span><span class="headingEndMark"> — </span>An inherited syndrome of hyperkalemia, volume expansion, hypertension, and otherwise normal kidney function has been called pseudohypoaldosteronism type 2, Gordon's syndrome, or familial hyperkalemic hypertension. The reduction in aldosterone secretion represents an <strong>appropriate</strong> response to volume expansion. (See  <a class="medical medical_review" href="/z/d/html/2306.html" rel="external">"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)", section on 'Pseudohypoaldosteronism type 2 (Gordon's syndrome)'</a>.)</p><p class="headingAnchor" id="H19"><span class="h3">Ureterojejunostomy</span><span class="headingEndMark"> — </span>A rise in the serum potassium concentration can occur in patients with a urinary diversion procedure in which the ureters are inserted into the jejunum (called a ureterojejunostomy). Hyperkalemia in this setting is presumably due to absorption of urinary potassium by the jejunum [<a href="#rid103">103</a>]. (See  <a class="medical medical_review" href="/z/d/html/2320.html" rel="external">"Acid-base and electrolyte abnormalities with diarrhea"</a>.)</p><p class="headingAnchor" id="H156422221"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Evaluation of the patient with hyperkalemia usually begins with a careful history, evaluation for clinical manifestations of hyperkalemia such as muscle weakness and characteristic changes on the electrocardiogram, and laboratory testing for the causes of hyperkalemia (<a class="graphic graphic_algorithm graphicRef109740" href="/z/d/graphic/109740.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/2342.html" rel="external">"Clinical manifestations of hyperkalemia in adults"</a>.)</p><p class="headingAnchor" id="H156422773"><span class="h2">Exclude pseudohyperkalemia</span><span class="headingEndMark"> — </span>Pseudohyperkalemia, which is discussed above, refers to those conditions in which the elevation in the measured serum potassium concentration is due to potassium movement out of the cells during or after the blood specimen has been drawn. It is usually related to the technique of blood drawing, but it can also occur in patients with marked elevations in platelet or white blood cell counts. (See <a class="local">'Pseudohyperkalemia'</a> above.)</p><p>Pseudohyperkalemia should be suspected when there is no apparent cause for the hyperkalemia in an asymptomatic patient who has no clinical or electrocardiographic manifestations of hyperkalemia. One clue to the possible presence of pseudohyperkalemia is wide variability in repeated measurements of the serum potassium concentration (eg, from 5 to 6.5 mEq/L, often including some normal values). In contrast, patients with normokalemia and those with true chronic hyperkalemia, most often due to hypoaldosteronism or chronic kidney disease, tend to have stable values over the short term, although higher values can occur over time if there is progression of the underlying disease.</p><p>If an artifact of blood drawing is suspected or there is no apparent cause for hyperkalemia, venipuncture without a tourniquet, repeated fist clenching, or trauma will demonstrate the true serum potassium concentration [<a href="#rid21">21</a>]. If a tourniquet is required, the tourniquet should be released after the needle has entered the vein, followed by waiting for one to two minutes before drawing the blood sample. The diagnosis of pseudohyperkalemia in patients with thrombocytosis or markedly elevated white blood cell counts is described above. (See <a class="local">'Other causes'</a> above.)</p><p class="headingAnchor" id="H156422795"><span class="h2">Acute rise in serum potassium</span><span class="headingEndMark"> — </span>In the absence of pseudohyperkalemia or recent potassium administration, an acute rise in serum potassium is often due to increased release of potassium from the cells, and the cause is identified from the history and laboratory data. Increased tissue catabolism is a classic example that is most often due to trauma or cytotoxic or radiation therapy in patients with lymphoma or leukemia (the tumor lysis syndrome). Diabetic ketoacidosis is another cause of an acute rise in serum potassium, a change that is more pronounced if kidney function is impaired. (See <a class="local">'Increased tissue catabolism'</a> above and <a class="local">'Insulin deficiency, hyperglycemia, and hyperosmolality'</a> above and <a class="local">'Metabolic acidosis'</a> above.) </p><p>Increasing potassium intake is <strong>not</strong> a major cause of hyperkalemia in individuals without another risk factor such as reduced aldosterone secretion or responsiveness or acute or chronic kidney disease. In healthy adults, raising potassium intake from a normal value of 100 mEq/day to a much higher value of 400 mEq/day only produces a modest elevation in serum potassium from 3.8 mEq/L at baseline to 4.8 mEq/L at the end of day 2 and 4.2 mEq/L at day 20 (<a class="graphic graphic_figure graphicRef50808" href="/z/d/graphic/50808.html" rel="external">figure 3</a>) [<a href="#rid10">10</a>]. Urinary potassium excretion increases to the level of intake by the end of the second day, an effect that is mediated by both the elevation in plasma potassium and increased secretion of aldosterone. (See <a class="local">'Potassium adaptation'</a> above.)</p><p class="headingAnchor" id="H873885"><span class="h2">Persistent hyperkalemia</span><span class="headingEndMark"> — </span>Given the ability of healthy individuals to handle large potassium loads with only a small rise in serum potassium (<a class="graphic graphic_figure graphicRef50808" href="/z/d/graphic/50808.html" rel="external">figure 3</a>) [<a href="#rid10">10</a>], the most common causes of persistent hyperkalemia are associated with impaired urinary potassium excretion due to reduced secretion of or response to aldosterone, acute or chronic kidney disease, and/or effective arterial blood volume depletion. Effective arterial blood volume depletion may be due to true volume depletion or to heart failure or cirrhosis, in which decreased tissue perfusion is due to a reduced cardiac output and vasodilation, respectively (<a class="graphic graphic_table graphicRef58157" href="/z/d/graphic/58157.html" rel="external">table 1</a>). (See <a class="local">'Reduced urinary potassium excretion'</a> above.)</p><p>Administration of angiotensin inhibitors and aldosterone antagonists in patients with heart failure can contribute to the development of hyperkalemia but can also improve patient outcomes [<a href="#rid104">104</a>]. Limiting potassium intake and the use of loop diuretics may minimize the degree of hyperkalemia and allow these potentially life-saving therapies to be continued. (See  <a class="medical medical_review" href="/z/d/html/2332.html" rel="external">"Treatment and prevention of hyperkalemia in adults", section on 'Prevention'</a> and  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Mineralocorticoid receptor antagonist'</a> and  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Hyperkalemia'</a>.)</p><p class="headingAnchor" id="H249933270"><span class="h3">Urinary potassium excretion</span><span class="headingEndMark"> — </span>Measurement of 24-hour urinary potassium excretion is of <strong>limited utility</strong> in patients with persistent <strong>stable</strong> hyperkalemia because urinary potassium excretion is primarily determined by and roughly equal to potassium intake. These patients have an impairment in urinary potassium excretion since a higher-than-normal plasma potassium concentration is required to excrete the daily potassium load.</p><p>Although uncommon, 24-hour urinary potassium excretion above 80 to 100 mEq/day (normal potassium intake) suggests that increased potassium intake (as with ingestion of a salt substitute) may be contributing to the hyperkalemia. However, as noted above, increasing potassium intake alone is not sufficient in healthy adults. In this setting, raising potassium intake from 100 to 400 mEq/day only increases the serum potassium from 3.8 mEq/L at baseline to 4.8 mEq/L at the end of day 2 and 4.2 mEq/L by day 20, a time at which intake and output are again equal (<a class="graphic graphic_figure graphicRef50808" href="/z/d/graphic/50808.html" rel="external">figure 3</a>) [<a href="#rid10">10</a>]. (See <a class="local">'Potassium adaptation'</a> above.)</p><p class="headingAnchor" id="H249933336"><span class="h3">Transtubular potassium gradient</span><span class="headingEndMark"> — </span>It would be desirable to assess the degree of aldosterone activity in patients with hyperkalemia by estimating the tubular fluid potassium concentration at the most distal site of potassium secretion in the cortical collecting tubule. Although this measurement cannot be made in humans, it was proposed that the potassium concentration at this site could be estimated clinically from calculation of the transtubular potassium gradient (TTKG) [<a href="#rid105">105-107</a>].</p><p>However, in a later publication, the authors of the original studies suggested that the assumptions underlying the TTKG were <strong>not valid</strong> [<a href="#rid108">108</a>], suggested that the equation did not consider the effects of distal tubular urea reabsorption on potassium excretion, and concluded that the TTKG was not a reliable test for the diagnosis of hyperkalemia. However, these criticisms are theoretical and not supported by animal experiments [<a href="#rid109">109</a>]. Thus, it is unclear whether use of the TTKG is appropriate for assessment of the renal response to hyperkalemia. An alternative is the potassium:creatinine ratio; however, this calculation has not been extensively validated in hyperkalemia.</p><p class="headingAnchor" id="H249933454"><span class="h3">Diagnosis of hypoaldosteronism</span><span class="headingEndMark"> — </span>Patients with persistent hyperkalemia in whom the etiology has not been identified should be evaluated for the presence and cause of hypoaldosteronism. This disorder can result from reduced aldosterone secretion or from aldosterone resistance, which most often occurs in patients treated with potassium-sparing diuretics and can be one of several factors that can contribute to hyperkalemia in acute and chronic kidney disease. (See <a class="local">'Reduced aldosterone secretion'</a> above and <a class="local">'Reduced response to aldosterone'</a> above.)</p><p>The approach to the diagnosis of hypoaldosteronism is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2306.html" rel="external">"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)", section on 'Diagnosis of hypoaldosteronism'</a>.)</p><p class="headingAnchor" id="H2301258685"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109733.html" rel="external">"Society guideline links: Fluid and electrolyte disorders in adults"</a>.)</p><p class="headingAnchor" id="H114286098"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/17129.html" rel="external">"Patient education: Hyperkalemia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H783293332"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Ingestion of a potassium load leads initially to the uptake of most of the excess potassium by cells in muscle and the liver, a process that is facilitated by insulin and the beta-2-adrenergic receptors, both of which increase the activity of Na-K-ATPase pumps in the cell membrane. Some of the ingested potassium remains in the extracellular fluid, producing a mild elevation in the plasma potassium concentration. The increase in plasma potassium stimulates the secretion of aldosterone, which enhances both sodium reabsorption and potassium secretion by principal cells (<a class="graphic graphic_figure graphicRef60693" href="/z/d/graphic/60693.html" rel="external">figure 1</a>). (See <a class="local">'Brief review of potassium physiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increasing potassium intake alone is <strong>not</strong> a common cause of hyperkalemia unless it occurs acutely. The net release of potassium from the cells (due to enhanced release or decreased entry) can, if large enough (eg, increased tissue breakdown), cause a transient elevation in the serum potassium concentration. Persistent hyperkalemia requires <strong>impaired urinary potassium excretion</strong>. This is generally associated with a reduction in aldosterone secretion or responsiveness, acute or chronic kidney disease, and/or diminished delivery of sodium and water to the distal potassium secretory sites (<a class="graphic graphic_table graphicRef58157" href="/z/d/graphic/58157.html" rel="external">table 1</a>). (See <a class="local">'Brief review of potassium physiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The following are causes of hyperkalemia due to increased potassium release from cells (see <a class="local">'Increased potassium release from cells'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pseudohyperkalemia – Pseudohyperkalemia includes those conditions in which the elevation in the measured serum potassium concentration is due to potassium movement out of the cells during or after the blood specimen has been drawn. The most common is mechanical trauma during venipuncture, which can result in the release of potassium from red cells and a characteristic reddish tint of the serum due to the concomitant release of hemoglobin. (See <a class="local">'Pseudohyperkalemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Metabolic acidosis – In patients with metabolic acidosis other than organic acidosis due to lactic acidosis or ketoacidosis, buffering of excess hydrogen ions in the cells leads to potassium movement into the extracellular fluid, a transcellular shift that is obligated in part by the need to maintain electroneutrality (<a class="graphic graphic_figure graphicRef68866" href="/z/d/graphic/68866.html" rel="external">figure 4</a>). (See <a class="local">'Metabolic acidosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Insulin deficiency, hyperglycemia, and hyperosmolality – Insulin promotes potassium entry into cells, minimizing the rise in the serum potassium concentration induced by concurrent potassium intake (<a class="graphic graphic_figure graphicRef52424" href="/z/d/graphic/52424.html" rel="external">figure 5</a>). In uncontrolled diabetes mellitus, the combination of insulin deficiency/resistance and hyperosmolality induced by hyperglycemia frequently leads to hyperkalemia even though there may be marked potassium depletion due to urinary losses caused by the osmotic diuresis (<a class="graphic graphic_figure graphicRef64207" href="/z/d/graphic/64207.html" rel="external">figure 6</a>). (See <a class="local">'Insulin deficiency, hyperglycemia, and hyperosmolality'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased tissue catabolism – Any cause of increased tissue breakdown leads to the release of intracellular potassium into the extracellular fluid. Hyperkalemia can occur in this setting, particularly if kidney failure is also present. (See <a class="local">'Increased tissue catabolism'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Beta blockers – Beta blockers interfere with the beta-2-adrenergic facilitation of potassium uptake by the cells, particularly after a potassium load (<a class="graphic graphic_figure graphicRef62538" href="/z/d/graphic/62538.html" rel="external">figure 7</a>). An increase in serum potassium is primarily seen with nonselective beta blockers (such as <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> and <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">labetalol</a>).</p><p></p><p class="bulletIndent1">Other causes of hyperkalemia due to increased potassium release from cells include exercise, hyperkalemic periodic paralysis, red cell transfusion, and various drugs including digitalis. (See <a class="local">'Exercise'</a> above and <a class="local">'Hyperkalemic periodic paralysis'</a> above and <a class="local">'Other'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The four major causes of hyperkalemia due to reduced urinary potassium secretion are (<a class="graphic graphic_table graphicRef58157" href="/z/d/graphic/58157.html" rel="external">table 1</a>) (see <a class="local">'Reduced urinary potassium excretion'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduced aldosterone secretion – Any cause of decreased aldosterone release, such as that induced by hyporeninemic hypoaldosteronism or certain drugs, can diminish the efficiency of potassium secretion and lead to hyperkalemia and metabolic acidosis (called type 4 renal tubular acidosis [RTA]) (<a class="graphic graphic_table graphicRef82440" href="/z/d/graphic/82440.html" rel="external">table 2</a>). (See <a class="local">'Reduced aldosterone secretion'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduced response to aldosterone (aldosterone resistance) – There are a number of causes of hyperkalemia that are due to a reduced response to aldosterone, also called aldosterone or mineralocorticoid resistance. The most common are the administration of potassium-sparing diuretics and acute and chronic kidney disease. (See <a class="local">'Reduced response to aldosterone'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduced distal sodium and water delivery – Potassium secretion can be impaired if there is a substantial reduction in sodium and water delivery to the potassium secretory sites in the distal nephron (connecting segment and cortical collecting tubule). The most common cause is reduced effective arterial blood volume, including any cause of true volume depletion (eg, gastrointestinal or renal losses) as well as heart failure and cirrhosis in which decreased tissue perfusion is due to a reduced cardiac output and vasodilation, respectively. (See <a class="local">'Reduced distal sodium and water delivery'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute and chronic kidney disease – In patients with acute kidney injury, hyperkalemia is most prevalent in oliguric patients who also have increased potassium release from cells due, for example, to rhabdomyolysis or tumor lysis syndrome. In patients with chronic kidney disease, the ability to excrete dietary potassium without the development of hyperkalemia generally persists as long as both the secretion of and responsiveness to aldosterone are intact and distal delivery of sodium and water are maintained. However, moderate increases in potassium intake can be an important contributor to the development of hyperkalemia in patients with impaired potassium excretion due to kidney function impairment, particularly in combination with other predisposing factors (hyporeninemic hypoaldosteronism, angiotensin-converting enzyme [ACE] inhibitor therapy, etc). (See <a class="local">'Acute and chronic kidney disease'</a> above.)</p><p></p><p class="bulletIndent1">Other causes of impaired urinary potassium excretion include Gordon's syndrome and ureterojejunostomy. (See <a class="local">'Other mechanisms of impaired potassium secretion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of the patient with hyperkalemia usually begins with a careful history, evaluation for clinical manifestations of hyperkalemia such as muscle weakness and characteristic changes on the electrocardiogram, and laboratory testing for the causes of hyperkalemia (<a class="graphic graphic_algorithm graphicRef109740" href="/z/d/graphic/109740.html" rel="external">algorithm 1</a>). (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pseudohyperkalemia should be suspected when there is no apparent cause for the hyperkalemia in an asymptomatic patient who has no clinical or electrocardiographic manifestations of hyperkalemia. (See <a class="local">'Exclude pseudohyperkalemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the absence of pseudohyperkalemia or recent potassium administration, an acute rise in serum potassium is often due to increased release of potassium from the cells, and the cause is identified from the history and laboratory data. (See <a class="local">'Acute rise in serum potassium'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Given the ability of healthy individuals to handle large potassium loads with only a small rise in serum potassium (<a class="graphic graphic_figure graphicRef50808" href="/z/d/graphic/50808.html" rel="external">figure 3</a>), the most common causes of persistent hyperkalemia are associated with impaired urinary potassium excretion due to reduced secretion of or response to aldosterone, acute or chronic kidney disease, and/or effective arterial blood volume depletion. Measurement of 24-hour urinary potassium excretion is of <strong>limited utility</strong> in patients with persistent <strong>stable</strong> hyperkalemia. The transtubular potassium gradient (TTKG) may be used for the diagnosis of hyperkalemia, in combination with assessment of urine sodium. Patients with persistent hyperkalemia in whom the etiology has not been identified should be evaluated for the presence and cause of hypoaldosteronism. (See <a class="local">'Persistent hyperkalemia'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Boddy K, King PC, Hume R, Weyers E. The relation of total body potassium to height, weight, and age in normal adults. J Clin Pathol 1972; 25:512.</a></li><li><a class="nounderline abstract_t">Wang WH, Giebisch G. Regulation of potassium (K) handling in the renal collecting duct. Pflugers Arch 2009; 458:157.</a></li><li><a class="nounderline abstract_t">Giebisch GH, Wang WH. Potassium transport--an update. J Nephrol 2010; 23 Suppl 16:S97.</a></li><li><a class="nounderline abstract_t">Youn JH, McDonough AA. Recent advances in understanding integrative control of potassium homeostasis. Annu Rev Physiol 2009; 71:381.</a></li><li class="breakAll">Mount DB, Zandi-Nejad K. Disorders of potassium balance. In: Brenner and Rector's The Kidney, 9th Ed, WB Saunders &amp; Company, Philadelphia 2011. p.640.</li><li><a class="nounderline abstract_t">Clausen T, Everts ME. Regulation of the Na,K-pump in skeletal muscle. Kidney Int 1989; 35:1.</a></li><li><a class="nounderline abstract_t">Bundgaard H, Schmidt TA, Larsen JS, Kjeldsen K. K+ supplementation increases muscle [Na+-K+-ATPase] and improves extrarenal K+ homeostasis in rats. J Appl Physiol (1985) 1997; 82:1136.</a></li><li><a class="nounderline abstract_t">Palmer LG, Frindt G. Regulation of apical K channels in rat cortical collecting tubule during changes in dietary K intake. Am J Physiol 1999; 277:F805.</a></li><li><a class="nounderline abstract_t">Jackson CA. Rapid renal potassium adaptation in rats. Am J Physiol 1992; 263:F1098.</a></li><li><a class="nounderline abstract_t">Rabelink TJ, Koomans HA, Hené RJ, Dorhout Mees EJ. Early and late adjustment to potassium loading in humans. Kidney Int 1990; 38:942.</a></li><li><a class="nounderline abstract_t">Frindt G, Shah A, Edvinsson J, Palmer LG. Dietary K regulates ROMK channels in connecting tubule and cortical collecting duct of rat kidney. Am J Physiol Renal Physiol 2009; 296:F347.</a></li><li><a class="nounderline abstract_t">Garg LC, Narang N. Renal adaptation to potassium in the adrenalectomized rabbit. Role of distal tubular sodium-potassium adenosine triphosphatase. J Clin Invest 1985; 76:1065.</a></li><li><a class="nounderline abstract_t">Mujais SK. Renal memory after potassium adaptation: role of Na+-K+-ATPase. Am J Physiol 1988; 254:F845.</a></li><li><a class="nounderline abstract_t">Palmer LG, Antonian L, Frindt G. Regulation of apical K and Na channels and Na/K pumps in rat cortical collecting tubule by dietary K. J Gen Physiol 1994; 104:693.</a></li><li><a class="nounderline abstract_t">Terker AS, Zhang C, McCormick JA, et al. Potassium modulates electrolyte balance and blood pressure through effects on distal cell voltage and chloride. Cell Metab 2015; 21:39.</a></li><li><a class="nounderline abstract_t">Poulsen SB, Fenton RA. K+ and the renin-angiotensin-aldosterone system: new insights into their role in blood pressure control and hypertension treatment. J Physiol 2019; 597:4451.</a></li><li><a class="nounderline abstract_t">Nomura N, Shoda W, Uchida S. Clinical importance of potassium intake and molecular mechanism of potassium regulation. Clin Exp Nephrol 2019; 23:1175.</a></li><li><a class="nounderline abstract_t">Smellie WS. Spurious hyperkalaemia. BMJ 2007; 334:693.</a></li><li><a class="nounderline abstract_t">Ismail A, Shingler W, Seneviratne J, Burrows G. In vitro and in vivo haemolysis and potassium measurement. BMJ 2005; 330:949.</a></li><li><a class="nounderline abstract_t">Don BR, Sebastian A, Cheitlin M, et al. Pseudohyperkalemia caused by fist clenching during phlebotomy. N Engl J Med 1990; 322:1290.</a></li><li><a class="nounderline abstract_t">Wiederkehr MR, Moe OW. Factitious hyperkalemia. Am J Kidney Dis 2000; 36:1049.</a></li><li><a class="nounderline abstract_t">Bailey IR, Thurlow VR. Is suboptimal phlebotomy technique impacting on potassium results for primary care? Ann Clin Biochem 2008; 45:266.</a></li><li><a class="nounderline abstract_t">Graber M, Subramani K, Corish D, Schwab A. Thrombocytosis elevates serum potassium. Am J Kidney Dis 1988; 12:116.</a></li><li><a class="nounderline abstract_t">Chumbley LC. Pseudohyperkalemia in acute myelocytic leukemia. JAMA 1970; 211:1007.</a></li><li><a class="nounderline abstract_t">Lee HK, Brough TJ, Curtis MB, et al. Pseudohyperkalemia--is serum or whole blood a better specimen type than plasma? Clin Chim Acta 2008; 396:95.</a></li><li><a class="nounderline abstract_t">Chawla NR, Shapiro J, Sham RL. Pneumatic tube "pseudo tumor lysis syndrome" in chronic lymphocytic leukemia. Am J Hematol 2009; 84:613.</a></li><li><a class="nounderline abstract_t">Kellerman PS, Thornbery JM. Pseudohyperkalemia due to pneumatic tube transport in a leukemic patient. Am J Kidney Dis 2005; 46:746.</a></li><li><a class="nounderline abstract_t">Adrogué HJ, Madias NE. Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med 1981; 71:456.</a></li><li><a class="nounderline abstract_t">Aronson PS, Giebisch G. Effects of pH on potassium: new explanations for old observations. J Am Soc Nephrol 2011; 22:1981.</a></li><li><a class="nounderline abstract_t">Fulop M. Serum potassium in lactic acidosis and ketoacidosis. N Engl J Med 1979; 300:1087.</a></li><li><a class="nounderline abstract_t">Orringer CE, Eustace JC, Wunsch CD, Gardner LB. Natural history of lactic acidosis after grand-mal seizures. A model for the study of an anion-gap acidosis not associated with hyperkalemia. N Engl J Med 1977; 297:796.</a></li><li><a class="nounderline abstract_t">Finsterer U, Lühr HG, Wirth AE. Effects of acute hypercapnia and hypocapnia on plasma and red cell potassium, blood lactate and base excess in man during anesthesia. Acta Anaesthesiol Scand 1978; 22:353.</a></li><li><a class="nounderline abstract_t">SCRIBNER BH, FREMONT-SMITH K, BURNELL JM. The effect of acute respiratory acidosis on the internal equilibrium of potassium. J Clin Invest 1955; 34:1276.</a></li><li><a class="nounderline abstract_t">Magner PO, Robinson L, Halperin RM, et al. The plasma potassium concentration in metabolic acidosis: a re-evaluation. Am J Kidney Dis 1988; 11:220.</a></li><li><a class="nounderline abstract_t">COHEN JJ, BRACKETT NC Jr, SCHWARTZ WB. THE NATURE OF THE CARBON DIOXIDE TITRATION CURVE IN THE NORMAL DOG. J Clin Invest 1964; 43:777.</a></li><li><a class="nounderline abstract_t">Allon M, Dansby L, Shanklin N. Glucose modulation of the disposal of an acute potassium load in patients with end-stage renal disease. Am J Med 1993; 94:475.</a></li><li><a class="nounderline abstract_t">Nicolis GL, Kahn T, Sanchez A, Gabrilove JL. Glucose-induced hyperkalemia in diabetic subjects. Arch Intern Med 1981; 141:49.</a></li><li><a class="nounderline abstract_t">Adrogué HJ, Lederer ED, Suki WN, Eknoyan G. Determinants of plasma potassium levels in diabetic ketoacidosis. Medicine (Baltimore) 1986; 65:163.</a></li><li><a class="nounderline abstract_t">Viberti GC. Glucose-induced hyperkalaemia: A hazard for diabetics? Lancet 1978; 1:690.</a></li><li><a class="nounderline abstract_t">DeFronzo RA, Sherwin RS, Dillingham M, et al. Influence of basal insulin and glucagon secretion on potassium and sodium metabolism. Studies with somatostatin in normal dogs and in normal and diabetic human beings. J Clin Invest 1978; 61:472.</a></li><li><a class="nounderline abstract_t">Sharma AM, Thiede HM, Keller F. Somatostatin-induced hyperkalemia in a patient on maintenance hemodialysis. Nephron 1991; 59:445.</a></li><li><a class="nounderline abstract_t">Adabala M, Jhaveri KD, Gitman M. Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient. Nephrol Dial Transplant 2010; 25:3439.</a></li><li><a class="nounderline abstract_t">Sargent AI, Overton CC, Kuwik RJ, et al. Octreotide-induced hyperkalemia. Pharmacotherapy 1994; 14:497.</a></li><li><a class="nounderline abstract_t">Conte G, Dal Canton A, Imperatore P, et al. Acute increase in plasma osmolality as a cause of hyperkalemia in patients with renal failure. Kidney Int 1990; 38:301.</a></li><li><a class="nounderline abstract_t">Daphnis E, Stylianou K, Alexandrakis M, et al. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy. Nephron Clin Pract 2007; 106:c143.</a></li><li><a class="nounderline abstract_t">Sirken G, Raja R, Garces J, et al. Contrast-induced translocational hyponatremia and hyperkalemia in advanced kidney disease. Am J Kidney Dis 2004; 43:e31.</a></li><li><a class="nounderline abstract_t">Manninen PH, Lam AM, Gelb AW, Brown SC. The effect of high-dose mannitol on serum and urine electrolytes and osmolality in neurosurgical patients. Can J Anaesth 1987; 34:442.</a></li><li><a class="nounderline abstract_t">Sever MS, Erek E, Vanholder R, et al. Serum potassium in the crush syndrome victims of the Marmara disaster. Clin Nephrol 2003; 59:326.</a></li><li><a class="nounderline abstract_t">Perkins RM, Aboudara MC, Abbott KC, Holcomb JB. Resuscitative hyperkalemia in noncrush trauma: a prospective, observational study. Clin J Am Soc Nephrol 2007; 2:313.</a></li><li><a class="nounderline abstract_t">Schaller MD, Fischer AP, Perret CH. Hyperkalemia. A prognostic factor during acute severe hypothermia. JAMA 1990; 264:1842.</a></li><li><a class="nounderline abstract_t">Rosa RM, Silva P, Young JB, et al. Adrenergic modulation of extrarenal potassium disposal. N Engl J Med 1980; 302:431.</a></li><li><a class="nounderline abstract_t">Arthur S, Greenberg A. Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. Clin Nephrol 1990; 33:269.</a></li><li><a class="nounderline abstract_t">Reid JL, Whyte KF, Struthers AD. Epinephrine-induced hypokalemia: the role of beta adrenoceptors. Am J Cardiol 1986; 57:23F.</a></li><li><a class="nounderline abstract_t">Lim M, Linton RA, Wolff CB, Band DM. Propranolol, exercise, and arterial plasma potassium. Lancet 1981; 2:591.</a></li><li><a class="nounderline abstract_t">Daut J, Maier-Rudolph W, von Beckerath N, et al. Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels. Science 1990; 247:1341.</a></li><li><a class="nounderline abstract_t">Castellino P, Bia MJ, DeFronzo RA. Adrenergic modulation of potassium metabolism in uremia. Kidney Int 1990; 37:793.</a></li><li><a class="nounderline abstract_t">Struthers AD, Quigley C, Brown MJ. Rapid changes in plasma potassium during a game of squash. Clin Sci (Lond) 1988; 74:397.</a></li><li><a class="nounderline abstract_t">Thomson A, Kelly DT. Exercise stress-induced changes in systemic arterial potassium in angina pectoris. Am J Cardiol 1989; 63:1435.</a></li><li><a class="nounderline abstract_t">Lindinger MI, Heigenhauser GJ, McKelvie RS, Jones NL. Blood ion regulation during repeated maximal exercise and recovery in humans. Am J Physiol 1992; 262:R126.</a></li><li><a class="nounderline abstract_t">Knochel JP, Blachley JD, Johnson JH, Carter NW. Muscle cell electrical hyperpolarization and reduced exercise hyperkalemia in physically conditioned dogs. J Clin Invest 1985; 75:740.</a></li><li><a class="nounderline abstract_t">Sangkabutra T, Crankshaw DP, Schneider C, et al. Impaired K+ regulation contributes to exercise limitation in end-stage renal failure. Kidney Int 2003; 63:283.</a></li><li><a class="nounderline abstract_t">Reza MJ, Kovick RB, Shine KI, Pearce ML. Massive intravenous digoxin overdosage. N Engl J Med 1974; 291:777.</a></li><li><a class="nounderline abstract_t">Bandara V, Weinstein SA, White J, Eddleston M. A review of the natural history, toxinology, diagnosis and clinical management of Nerium oleander (common oleander) and Thevetia peruviana (yellow oleander) poisoning. Toxicon 2010; 56:273.</a></li><li><a class="nounderline abstract_t">Gowda RM, Cohen RA, Khan IA. Toad venom poisoning: resemblance to digoxin toxicity and therapeutic implications. Heart 2003; 89:e14.</a></li><li><a class="nounderline abstract_t">Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology 2006; 104:158.</a></li><li><a class="nounderline abstract_t">Birch AA Jr, Mitchell GD, Playford GA, Lang CA. Changes in serum potassium response to succinylcholine following trauma. JAMA 1969; 210:490.</a></li><li><a class="nounderline abstract_t">Cooperman LH. Succinylcholine-induced hyperkalemia in neuromuscular disease. JAMA 1970; 213:1867.</a></li><li><a class="nounderline abstract_t">Bushinsky DA, Gennari FJ. Life-threatening hyperkalemia induced by arginine. Ann Intern Med 1978; 89:632.</a></li><li><a class="nounderline abstract_t">Perazella MA, Biswas P. Acute hyperkalemia associated with intravenous epsilon-aminocaproic acid therapy. Am J Kidney Dis 1999; 33:782.</a></li><li><a class="nounderline abstract_t">Nzerue CM, Falana B. Refractory hyperkalaemia associated with use of epsilon-aminocaproic acid during coronary bypass in a dialysis patient. Nephrol Dial Transplant 2002; 17:1150.</a></li><li><a class="nounderline abstract_t">Singer M, Coluzzi F, O'Brien A, Clapp LH. Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. Lancet 2005; 365:1873.</a></li><li><a class="nounderline abstract_t">Lee HH, Hsu PC, Lin TH, et al. Nicorandil-induced hyperkalemia in a uremic patient. Case Rep Med 2012; 2012:812178.</a></li><li><a class="nounderline abstract_t">Chen HT, Wu YT, Yang WC, et al. Nicorandil-Induced Hyperkalemia in a Hemodialysis Patient. Am J Med Sci 2017; 353:411.</a></li><li><a class="nounderline abstract_t">Chowdhry V, Mohanty BB. Intractable hyperkalemia due to nicorandil induced potassium channel syndrome. Ann Card Anaesth 2015; 18:101.</a></li><li class="breakAll">Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.383, 898.</li><li><a class="nounderline abstract_t">Chang AR, Sang Y, Leddy J, et al. Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System. Hypertension 2016; 67:1181.</a></li><li><a class="nounderline abstract_t">Velázquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993; 119:296.</a></li><li><a class="nounderline abstract_t">Kleyman TR, Roberts C, Ling BN. A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport. Ann Intern Med 1995; 122:103.</a></li><li><a class="nounderline abstract_t">Muto S, Tsuruoka S, Miyata Y, et al. Effect of trimethoprim-sulfamethoxazole on Na and K+ transport properties in the rabbit cortical collecting duct perfused in vitro. Nephron Physiol 2006; 102:p51.</a></li><li><a class="nounderline abstract_t">Choi MJ, Fernandez PC, Patnaik A, et al. Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med 1993; 328:703.</a></li><li><a class="nounderline abstract_t">Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996; 124:316.</a></li><li><a class="nounderline abstract_t">Batlle DC, Arruda JA, Kurtzman NA. Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy. N Engl J Med 1981; 304:373.</a></li><li><a class="nounderline abstract_t">Bastani B, Underhill D, Chu N, et al. Preservation of intercalated cell H(+)-ATPase in two patients with lupus nephritis and hyperkalemic distal renal tubular acidosis. J Am Soc Nephrol 1997; 8:1109.</a></li><li><a class="nounderline abstract_t">Batlle D, Itsarayoungyuen K, Arruda JA, Kurtzman NA. Hyperkalemic hyperchloremic metabolic acidosis in sickle cell hemoglobinopathies. Am J Med 1982; 72:188.</a></li><li><a class="nounderline abstract_t">Luke RG, Allison ME, Davidson JF, Duguid WP. Hyperkalemia and renal tubular acidosis due to renal amyloidosis. Ann Intern Med 1969; 70:1211.</a></li><li><a class="nounderline abstract_t">Stokes JB. Potassium secretion by cortical collecting tubule: relation to sodium absorption, luminal sodium concentration, and transepithelial voltage. Am J Physiol 1981; 241:F395.</a></li><li><a class="nounderline abstract_t">Giebisch G. Renal potassium transport: mechanisms and regulation. Am J Physiol 1998; 274:F817.</a></li><li><a class="nounderline abstract_t">Chakko SC, Frutchey J, Gheorghiade M. Life-threatening hyperkalemia in severe heart failure. Am Heart J 1989; 117:1083.</a></li><li><a class="nounderline abstract_t">Popovtzer MM, Katz FH, Pinggera WF, et al. Hyperkalemia in salt-wasting nephropathy. Study of the mechanism. Arch Intern Med 1973; 132:203.</a></li><li><a class="nounderline abstract_t">Gonick HC, Kleeman CR, Rubini ME, Maxwell MH. Functional impairment in chronic renal disease. 3. Studies of potassium excretion. Am J Med Sci 1971; 261:281.</a></li><li><a class="nounderline abstract_t">Allon M. Hyperkalemia in end-stage renal disease: mechanisms and management. J Am Soc Nephrol 1995; 6:1134.</a></li><li><a class="nounderline abstract_t">Allon M, Takeshian A, Shanklin N. Effect of insulin-plus-glucose infusion with or without epinephrine on fasting hyperkalemia. Kidney Int 1993; 43:212.</a></li><li><a class="nounderline abstract_t">Bonilla S, Goecke IA, Bozzo S, et al. Effect of chronic renal failure on Na,K-ATPase alpha 1 and alpha 2 mRNA transcription in rat skeletal muscle. J Clin Invest 1991; 88:2137.</a></li><li><a class="nounderline abstract_t">Bofill P, Goecke IA, Bonilla S, et al. Tissue-specific modulation of Na, K-ATPase alpha-subunit gene expression in uremic rats. Kidney Int 1994; 45:672.</a></li><li><a class="nounderline abstract_t">Crop MJ, Hoorn EJ, Lindemans J, Zietse R. Hypokalaemia and subsequent hyperkalaemia in hospitalized patients. Nephrol Dial Transplant 2007; 22:3471.</a></li><li><a class="nounderline abstract_t">Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110:438.</a></li><li><a class="nounderline abstract_t">Wrenger E, Müller R, Moesenthin M, et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003; 327:147.</a></li><li><a class="nounderline abstract_t">Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351:543.</a></li><li><a class="nounderline abstract_t">Gross P, Pistrosch F. Hyperkalaemia: again. Nephrol Dial Transplant 2004; 19:2163.</a></li><li><a class="nounderline abstract_t">DeFronzo RA, Cooke CR, Goldberg M, et al. Impaired renal tubular potassium secretion in systemic lupus erythematosus. Ann Intern Med 1977; 86:268.</a></li><li><a class="nounderline abstract_t">DeFronzo RA, Goldberg M, Cooke CR, et al. Investigations into the mechanisms of hyperkalemia following renal transplantation. Kidney Int 1977; 11:357.</a></li><li><a class="nounderline abstract_t">DeFronzo RA, Taufield PA, Black H, et al. Impaired renal tubular potassium secretion in sickle cell disease. Ann Intern Med 1979; 90:310.</a></li><li><a class="nounderline abstract_t">Agarwal R, Afzalpurkar R, Fordtran JS. Pathophysiology of potassium absorption and secretion by the human intestine. Gastroenterology 1994; 107:548.</a></li><li><a class="nounderline abstract_t">Linde C, Bakhai A, Furuland H, et al. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom. J Am Heart Assoc 2019; 8:e012655.</a></li><li><a class="nounderline abstract_t">West ML, Marsden PA, Richardson RM, et al. New clinical approach to evaluate disorders of potassium excretion. Miner Electrolyte Metab 1986; 12:234.</a></li><li><a class="nounderline abstract_t">Ethier JH, Kamel KS, Magner PO, et al. The transtubular potassium concentration in patients with hypokalemia and hyperkalemia. Am J Kidney Dis 1990; 15:309.</a></li><li><a class="nounderline abstract_t">Choi MJ, Ziyadeh FN. The utility of the transtubular potassium gradient in the evaluation of hyperkalemia. J Am Soc Nephrol 2008; 19:424.</a></li><li><a class="nounderline abstract_t">Kamel KS, Halperin ML. Intrarenal urea recycling leads to a higher rate of renal excretion of potassium: an hypothesis with clinical implications. Curr Opin Nephrol Hypertens 2011; 20:547.</a></li><li><a class="nounderline abstract_t">Cil O, Esteva-Font C, Tas ST, et al. Salt-sparing diuretic action of a water-soluble urea analog inhibitor of urea transporters UT-A and UT-B in rats. Kidney Int 2015; 88:311.</a></li></ol></div><div id="topicVersionRevision">Topic 2377 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4625433" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The relation of total body potassium to height, weight, and age in normal adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18839206" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Regulation of potassium (K) handling in the renal collecting duct.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21170894" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Potassium transport--an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18759636" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Recent advances in understanding integrative control of potassium homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18759636" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Recent advances in understanding integrative control of potassium homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2540370" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Regulation of the Na,K-pump in skeletal muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9104850" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : K+ supplementation increases muscle [Na+-K+-ATPase] and improves extrarenal K+ homeostasis in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10564246" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Regulation of apical K channels in rat cortical collecting tubule during changes in dietary K intake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1481886" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Rapid renal potassium adaptation in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2266680" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Early and late adjustment to potassium loading in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19036846" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Dietary K regulates ROMK channels in connecting tubule and cortical collecting duct of rat kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2995442" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Renal adaptation to potassium in the adrenalectomized rabbit. Role of distal tubular sodium-potassium adenosine triphosphatase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2837908" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Renal memory after potassium adaptation: role of Na+-K+-ATPase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7836937" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Regulation of apical K and Na channels and Na/K pumps in rat cortical collecting tubule by dietary K.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25565204" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Potassium modulates electrolyte balance and blood pressure through effects on distal cell voltage and chloride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31294465" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : K+ and the renin-angiotensin-aldosterone system: new insights into their role in blood pressure control and hypertension treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31317362" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical importance of potassium intake and molecular mechanism of potassium regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17395950" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Spurious hyperkalaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15845977" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : In vitro and in vivo haemolysis and potassium measurement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2325722" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pseudohyperkalemia caused by fist clenching during phlebotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11054365" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Factitious hyperkalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18482914" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Is suboptimal phlebotomy technique impacting on potassium results for primary care?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3400632" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Thrombocytosis elevates serum potassium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5265803" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pseudohyperkalemia in acute myelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18638465" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pseudohyperkalemia--is serum or whole blood a better specimen type than plasma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19610017" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pneumatic tube "pseudo tumor lysis syndrome" in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16183430" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pseudohyperkalemia due to pneumatic tube transport in a leukemic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7025622" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Changes in plasma potassium concentration during acute acid-base disturbances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21980112" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effects of pH on potassium: new explanations for old observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34793" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Serum potassium in lactic acidosis and ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19702" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Natural history of lactic acidosis after grand-mal seizures. A model for the study of an anion-gap acidosis not associated with hyperkalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31756" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of acute hypercapnia and hypocapnia on plasma and red cell potassium, blood lactate and base excess in man during anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13242660" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The effect of acute respiratory acidosis on the internal equilibrium of potassium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3344745" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The plasma potassium concentration in metabolic acidosis: a re-evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14169507" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : THE NATURE OF THE CARBON DIOXIDE TITRATION CURVE IN THE NORMAL DOG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8498392" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Glucose modulation of the disposal of an acute potassium load in patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7447584" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Glucose-induced hyperkalemia in diabetic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3084904" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Determinants of plasma potassium levels in diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/76227" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Glucose-induced hyperkalaemia: A hazard for diabetics?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/621284" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Influence of basal insulin and glucagon secretion on potassium and sodium metabolism. Studies with somatostatin in normal dogs and in normal and diabetic human beings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1684641" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Somatostatin-induced hyperkalemia in a patient on maintenance hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610525" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7937289" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Octreotide-induced hyperkalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2402122" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Acute increase in plasma osmolality as a cause of hyperkalemia in patients with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17596722" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14750123" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Contrast-induced translocational hyponatremia and hyperkalemia in advanced kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3117392" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The effect of high-dose mannitol on serum and urine electrolytes and osmolality in neurosurgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12779093" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Serum potassium in the crush syndrome victims of the Marmara disaster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699430" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Resuscitative hyperkalemia in noncrush trauma: a prospective, observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2402043" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Hyperkalemia. A prognostic factor during acute severe hypothermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6101508" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Adrenergic modulation of extrarenal potassium disposal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2376088" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3010693" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Epinephrine-induced hypokalemia: the role of beta adrenoceptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6116039" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Propranolol, exercise, and arterial plasma potassium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2107575" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2308263" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Adrenergic modulation of potassium metabolism in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2895695" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Rapid changes in plasma potassium during a game of squash.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2729129" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Exercise stress-induced changes in systemic arterial potassium in angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1733331" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Blood ion regulation during repeated maximal exercise and recovery in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2982919" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Muscle cell electrical hyperpolarization and reduced exercise hyperkalemia in physically conditioned dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12472794" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Impaired K+ regulation contributes to exercise limitation in end-stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4414583" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Massive intravenous digoxin overdosage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20438743" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A review of the natural history, toxinology, diagnosis and clinical management of Nerium oleander (common oleander) and Thevetia peruviana (yellow oleander) poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12639891" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Toad venom poisoning: resemblance to digoxin toxicity and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16394702" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5394378" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Changes in serum potassium response to succinylcholine following trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5468914" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Succinylcholine-induced hyperkalemia in neuromuscular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/717931" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Life-threatening hyperkalemia induced by arginine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10196024" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Acute hyperkalemia associated with intravenous epsilon-aminocaproic acid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12032221" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Refractory hyperkalaemia associated with use of epsilon-aminocaproic acid during coronary bypass in a dialysis patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15924984" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23118767" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Nicorandil-induced hyperkalemia in a uremic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28317633" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Nicorandil-Induced Hyperkalemia in a Hemodialysis Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25566721" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Intractable hyperkalemia due to nicorandil induced potassium channel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25566721" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Intractable hyperkalemia due to nicorandil induced potassium channel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27067721" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8328738" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Renal mechanism of trimethoprim-induced hyperkalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7992983" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286787" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Effect of trimethoprim-sulfamethoxazole on Na and K+ transport properties in the rabbit cortical collecting duct perfused in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8433730" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8554227" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7453754" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9219160" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Preservation of intercalated cell H(+)-ATPase in two patients with lupus nephritis and hyperkalemic distal renal tubular acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7036725" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Hyperkalemic hyperchloremic metabolic acidosis in sickle cell hemoglobinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5789510" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Hyperkalemia and renal tubular acidosis due to renal amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7315964" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Potassium secretion by cortical collecting tubule: relation to sodium absorption, luminal sodium concentration, and transepithelial voltage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9612319" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Renal potassium transport: mechanisms and regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2711969" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Life-threatening hyperkalemia in severe heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4719548" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Hyperkalemia in salt-wasting nephropathy. Study of the mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5092154" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Functional impairment in chronic renal disease. 3. Studies of potassium excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589279" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Hyperkalemia in end-stage renal disease: mechanisms and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8433561" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effect of insulin-plus-glucose infusion with or without epinephrine on fasting hyperkalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1661300" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Effect of chronic renal failure on Na,K-ATPase alpha 1 and alpha 2 mRNA transcription in rat skeletal muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8196269" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Tissue-specific modulation of Na, K-ATPase alpha-subunit gene expression in uremic rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17848395" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Hypokalaemia and subsequent hyperkalaemia in hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11331054" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12869459" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15295047" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15299094" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Hyperkalaemia: again.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/842984" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Impaired renal tubular potassium secretion in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/330924" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Investigations into the mechanisms of hyperkalemia following renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34341" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Impaired renal tubular potassium secretion in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8039632" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Pathophysiology of potassium absorption and secretion by the human intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31711387" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3762510" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : New clinical approach to evaluate disorders of potassium excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2321642" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The transtubular potassium concentration in patients with hypokalemia and hyperkalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18216310" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The utility of the transtubular potassium gradient in the evaluation of hyperkalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21788894" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Intrarenal urea recycling leads to a higher rate of renal excretion of potassium: an hypothesis with clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25993324" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Salt-sparing diuretic action of a water-soluble urea analog inhibitor of urea transporters UT-A and UT-B in rats.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
